Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.

The New England journal of medicine - 1 Feb 2007

Tefferi Ayalew

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to JAK2 gene
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Polycythemia Vera

Share to Signal Transduction

Source

Identifiers

PMID: 17267904
DOI: 10.1056/NEJMp068293

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.PMID 17267904Read ↗

JAK2V617F Exon-14 Mutation Driven Polycythemia Vera.Semantic proximity Read ↗

A Clue in JAK2: Masked Polycythemia Vera.Semantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospectsSemantic proximity Read ↗

Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2Semantic proximity Read ↗

Polycythemia vera is not initiated by JAK2 mutationSemantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read ↗

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia veraSemantic proximity Read ↗

Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera.Semantic proximity Read ↗

Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.Semantic proximity Read ↗

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.